Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development stage company, is focused on safer, more effective, less invasive and more economical oncology and dermatology therapies. Currently, the company is conducting Phase 2 clinical trials of their proprietary drugs designed to treat psoriasis, metastatic melanoma, and atopic dermatitis. Provectus has developed multiple intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For further information, visit the Company’s web site at www.pvct.com.
- 18 years ago
QualityStocks
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Massimo Group (NASDAQ: MAMO) Terminates Proposed FST Acquisition, Refocuses on Internal Security Technology Development
Massimo Group (NASDAQ: MAMO), a manufacturer and distributor of powersports vehicles and mobility solutions, announced it has terminated its…
-
QualityStocksNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid…
-
QualityStocksNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Engages Nanosoft to Advance ONC010 Development Program
This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising.…